Scoop has an Ethical Paywall
Work smarter with a Pro licence Learn More

Video | Agriculture | Confidence | Economy | Energy | Employment | Finance | Media | Property | RBNZ | Science | SOEs | Tax | Technology | Telecoms | Tourism | Transport | Search

 

Sysmex New Zealand expands product portfolio

Sysmex New Zealand Limited

Sysmex New Zealand expands product portfolio to include OGT Cytocell

Effective 1st October, Sysmex New Zealand have announced that the company will be managing the direct sales of Oxford Gene Technology’s (OGT) Cytocell Fluorescence In SituHybridisation (FISH) products, under the guidance and expertise of regional headquarters Sysmex Asia Pacific.

In June 2017 Sysmex Corporation, Sysmex New Zealand’s parent company, announced an agreement with OGT to acquire all shares in the molecular genetics company. The decision for Sysmex New Zealand to assume responsibility for sales in the New Zealand market is an indication of the continuing positive relationship between Sysmex and OGT and their commitment to ensure the delivery of exceptional quality support for their end users.

Arjit Bhana, Sysmex New Zealand CEO said, “With over 20 years of business presence in New Zealand and 50 years globally, we remain committed to the delivery of high-quality service for Cytocell customers in New Zealand. We believe this new extension to our product portfolio supports our future growth and allows us to consolidate our position in the NZ healthcare market.”

“Adding the OGT Cytocell business will give our customers direct access to the cutting-edge technologies and innovations that Sysmex Group provide to the global market,” adds Sysmex New Zealand IVD Unit Business Manager Mohammed Othman, “and complements our existing expertise working with New Zealand diagnostic laboratories, supporting the critical role they provide in quality patient care.”

Advertisement - scroll to continue reading

Are you getting our free newsletter?

Subscribe to Scoop’s 'The Catch Up' our free weekly newsletter sent to your inbox every Monday with stories from across our network.

A market leader in in-vitro diagnostic (IVD) technologies, Sysmex has seen the acquisition of OGT as an opportunity to further expand their portfolio and reinforce their technology base in the life science business. OGT’s Cytocell brand offers the largest range of superior, dependable, and cost-effective FISH probes on the market.

About Sysmex

Sysmex New Zealand is a subsidiary of Sysmex Corporation of Japan and specialises in the delivery and implementation of clinical IVD and health IT products and services for clinical laboratories, hospitals and healthcare organisations. Globally, Sysmex delivers total solutions in the field of clinical laboratory testing, including haematology, haemostasis, urinalysis, clinical chemistry, immunoassay systems, flow cytometry and life science, supplying products and services to customers in more than 160 countries.


ends

© Scoop Media

Advertisement - scroll to continue reading
 
 
 
Business Headlines | Sci-Tech Headlines

 
 
 
 
 
 
 
 
 
 
 
 

Join Our Free Newsletter

Subscribe to Scoop’s 'The Catch Up' our free weekly newsletter sent to your inbox every Monday with stories from across our network.